BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Core Insights - BioLineRx Ltd. has established a joint venture with Hemispherian AS to develop GLIX1, an oral small molecule targeting DNA damage response in glioblastoma and other cancers, with a Phase 1/2a clinical trial expected to start in Q1 2026 [1][15] - The company reported unaudited financial results for Q3 2025, highlighting a net loss of $1.0 million, a significant reduction from a net loss of $5.8 million in Q3 2024 [11][16] Corporate Updates - The joint venture with Hemispherian aims to expand BioLineRx's development pipeline into high-need cancer indications, particularly glioblastoma, which has a projected global market of over $3.7 billion by 2030 [6][15] - The ongoing CheMo4METPANC Phase 2b clinical trial of motixafortide in metastatic pancreatic cancer continues to progress, providing another opportunity for innovation in cancer treatment [2][12] Financial Updates - As of September 30, 2025, BioLineRx had $25.2 million in cash, sufficient to fund operations into the first half of 2027 [4][16] - Total revenues for Q3 2025 were $0.4 million, primarily from royalties related to the commercialization of APHEXDA, compared to $4.9 million in Q3 2024 [11][20] - Research and development expenses decreased by 33% to $1.7 million in Q3 2025, attributed to lower costs associated with motixafortide following the out-licensing of U.S. rights [16][20] Clinical Updates - Preparations for the Phase 1/2a clinical trial of GLIX1 in glioblastoma are advancing, with leading investigators from Northwestern University set to oversee the study [7][12] - The trial will assess GLIX1 as a monotherapy and in combination with standard care and PARP inhibitors in various cancer types [12][15] - A poster presentation at the upcoming ASH Annual Meeting will feature results from a Phase 1 trial evaluating motixafortide for mobilizing CD34+ hematopoietic stem cells in sickle cell disease [12][16]